Needham & Company LLC Has Lowered Expectations for Generation Bio (NASDAQ:GBIO) Stock Price

Generation Bio (NASDAQ:GBIO) had its price target reduced by Needham & Company LLC from $10.00 to $8.00 in a research report report published on Wednesday morning,Benzinga reports. They currently have a buy rating on the stock.

Separately, Wedbush reaffirmed an “outperform” rating and issued a $5.00 price objective on shares of Generation Bio in a research note on Thursday, November 7th.

Generation Bio Stock Down 12.5 %

Shares of NASDAQ:GBIO opened at $0.91 on Wednesday. Generation Bio has a 12-month low of $0.75 and a 12-month high of $4.65. The firm has a market capitalization of $60.79 million, a P/E ratio of -0.42 and a beta of 2.72. The firm has a fifty day moving average of $1.43 and a two-hundred day moving average of $2.18.

Institutional Trading of Generation Bio

A number of institutional investors and hedge funds have recently modified their holdings of the company. SG Americas Securities LLC bought a new stake in shares of Generation Bio in the 3rd quarter valued at approximately $42,000. Cubist Systematic Strategies LLC lifted its holdings in shares of Generation Bio by 91.0% during the second quarter. Cubist Systematic Strategies LLC now owns 19,046 shares of the company’s stock valued at $54,000 after acquiring an additional 9,075 shares during the period. American Century Companies Inc. boosted its stake in shares of Generation Bio by 199.3% in the 2nd quarter. American Century Companies Inc. now owns 31,786 shares of the company’s stock valued at $90,000 after purchasing an additional 21,167 shares in the last quarter. Barclays PLC grew its holdings in shares of Generation Bio by 165.5% in the 3rd quarter. Barclays PLC now owns 76,430 shares of the company’s stock worth $189,000 after purchasing an additional 47,639 shares during the last quarter. Finally, Rhumbline Advisers lifted its holdings in Generation Bio by 7.4% during the 2nd quarter. Rhumbline Advisers now owns 78,903 shares of the company’s stock valued at $222,000 after purchasing an additional 5,430 shares during the last quarter. 95.22% of the stock is currently owned by institutional investors.

About Generation Bio

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.